November 25, 2025 — Novo Nordisk made a bold gamble on oral semaglutide for delaying the progression of Alzheimer’s disease. Yesterday, as can happen with bold gambles, it did not pay off. A daily 14 mg oral dose of semaglutide was no better than placebo for preventing disease progression as measured by the Clinical Dementia Rating – Sum of […]
November 7, 2025 — President Trump held a press event yesterday to issue some very welcome news on coverage and prices for obesity medicines. On prices, they are coming down. In reality, this is an extension of the ongoing trend of downward pressure on these prices that has been in play since the day that semaglutide and tirzepatide launched […]
November 6, 2025 — At ObesityWeek in Atlanta, people are speculating about innovations that health professionals in general practice can embrace widely. We’re getting a good look at two candidates to become the GP GLP-1. Providing real obesity care and prescribing these medicines for more than a small portion of patients who need them is far from the norm. […]
November 1, 2025 — We’re packing our bags and scanning the meeting app for ObesityWeek in Atlanta, November 4-7. This promises to be a very intense week, with the biggest attendance yet for this signature meeting of the Obesity Society. The agenda for the week has a lot of options and we are still processing them all. But for […]
September 19, 2025 — The emerging contest to dominate the market for oral tablets in obesity treatment became clear this week as news and PR dispatches flowed from EASD in Vienna. Aiming for a Mass Target With understated confidence, Lilly presented and published pivotal phase three data on orforglipron in NEJM. They did not run from the fact that […]
March 30, 2025 — The opening of the American College of Cardiology meeting in Chicago yielded good news on semaglutide from two major studies. A morning presentation and simultaneous publication in Lancet showed semaglutide reduces symptoms of peripheral artery disease in persons with diabetes. Then, in the afternoon, researchers presented data and published it in the New England Journal […]
December 2, 2023 — Dozens of new obesity medicines are in the pipeline for clinical development. Some folks are especially interested in oral medicines that are small molecules. They’re looking for something that offers a sharp contrast with the complex peptide molecules (like semaglutide) given by injection, which are expensive and hard to make. One of the small, orally […]
May 23, 2023 — A pair of reports on Monday raised the possibility that we may soon have oral obesity meds that match the remarkable effectiveness of injections. One of these drugs is an oral formulation of semaglutide that’s already available at a much lower oral dose for diabetes under the brand name of Rybelsus. Novo Nordisk makes it. […]
March 27, 2023 — While Ozempic and Wegovy – two injectable forms of semaglutide – have been grabbing headlines, an oral tablet form – Rybelsus – has been quietly building momentum. Right now, it’s only approved for use in type 2 diabetes. But on Friday, Novo Nordisk announced results from the first phase 3 study of oral semaglutide for […]
June 8, 2021 — The mantra for the Wegovy brand of semaglutide just approved by FDA for obesity is clear enough – game changer. Great. Obesity is not a game, but health plans treat it like a 19th century game of hot potato: “Jack’s alive, and likely to live If he dies in your hand, you’ve a forfeit to […]
